No more accelerated approvals for PI3K? Biotech cites FDA's 'current position' as it warns of major delay

Did the FDA change its mind about the class of blood cancer drugs known as PI3K?

Whereas the agency had previously granted accelerated approvals to …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

No more ac­cel­er­at­ed ap­provals for PI3K? Biotech cites FDA's 'cur­rent po­si­tion' as it warns of ma­jor de­lay